Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.51 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509623 | 0.80 | PTGDR2 (0.53) | PTGDR2AKR1B1LIPEMCL1HTR1A | |
| SCHEMBL3005489 | 0.73 | PTGDR2 (0.48) | PTGDR2AKR1B1LIPEMCL1HTR1A | |
| SCHEMBL1385122 | 0.69 | PTGDR2 (0.87) | PTGDR2AKR1B1 | |
| SCHEMBL1385757 | 0.69 | PTGDR2 (0.75) | PTGDR2AKR1B1MCL1 | |
| SCHEMBL6509296 | 0.69 | PTGDR2 (0.41) | PTGDR2AKR1B1LIPEMCL1HTR1A | |
| SCHEMBL1386058 | 0.68 | PTGDR2 (0.73) | PTGDR2AKR1B1 | |
| SCHEMBL1788367 | 0.68 | PTGDR2 (1.00) | PTGDR2AKR1B1PTGDR | |
| SCHEMBL1386057 | 0.68 | PTGDR2 (0.62) | PTGDR2AKR1B1MCL1HTR6 | |
| SCHEMBL1386979 | 0.68 | PTGDR2 (1.00) | PTGDR2AKR1B1 | |
| SCHEMBL6512250 | 0.67 | PTGDR2 (0.63) | PTGDR2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197756-A1 | Indole-3-Sulphur Derivatives | ASTRAZENECA AB (SE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197756-A1 | Indole-3-Sulphur Derivatives | IDO1, IDO2, INMT | PTGDR2 525/4885AKR1B1 1827/4885LIPE 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.